The Cornelian dilemma † of quitting DAPT
Résumé
The journey from monotherapy to dual therapy In contrast to primary prevention, 1,2 the status of aspirin in the treatment of vascular diseases caused by atherothrombosis is unquestionable and unshakable. In addition to its undeniable efficiency, its affordability is a significant extra benefit. However, preventing thrombosis after iatrogenic disruption of the inner surface of a vessel wall by implantation of an intracoronary stent needs more than the antithrombotic efficacy of aspirin. Many advances in coronary intervention were made possible by extending single antiplatelet therapy (APT) to dual antiplatelet therapy (DAPT), which was done best by adding a P2Y 12 receptor inhibitor. Inhibition of platelet haemostatic function by suppressing the
Origine | Publication financée par une institution |
---|